In 2007, More Than 3 Million New Cases Of Solid Cancer Tumours Are Forecast To Be Diagnosed Across The Seven Major Pharmaceutical Markets
Research and Markets (http://www.researchandmarkets.com/reports/c72141) has announced the addition of “Pipeline Insight: Cancer Overview – Increasing diversity offers both high risk and reward” to their offering.
Introduction
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
Scope
Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for 17 tumor types Seven major pharmaceutical sales forecasts for Phase III pipeline products through to 2016 with product-specific assumptions Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights
The current solid tumor pipeline contains at least 707 unique agents, 9% of which are in late-phase development. These products cover a vast array of anticancer drug classes, including antihormonal therapies, cytotoxics, gene therapies, immunotherapies, photodynamic therapies, radiotherapeutics, targeted therapies and therapeutic vaccines. The late-phase pipeline contains equal amounts of cytotoxics and targeted therapies. The Phase I and II pipelines contain more than twice as many targeted therapies as cytotoxics. As such, it is clear that increasing diversity in terms of drug targets may result in greater treatment options in years to come if positive clinical data is generated. Despite high levels of unmet need and relatively healthy pipelines for most indications, no major breakthroughs are expected by current late-phase products aside from incremental increases in efficacy and reduced toxicity. This indicates a heavy reliance on the earlier-phase pipeline for further breakthroughs in terms of treatment of solid tumors.
Reasons to Purchase
Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2016 and Datamonitor drug assessment Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
For more information, visit http://www.researchandmarkets.com/reports/c72141
Source: Datamonitor